Head-to-head · WeighScore
Gimme Care vs Kongo
By GLP-1 ScorecardUpdated
Score comparison
Gimme Care has the higher recorded score — 84.6/100 to 83.8/100, but only just.
Gimme Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bundled compounded injections with lower advertised rates on longer plans; confirm the initial charge and renewal dates. Kongo is close behind and may still be the better fit — see the factor split below.
Before you choose
Before comparing the headline prices, the Gimme Care review and the Kongo review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Gimme Care vs Lavender Sky Health and Green Cap Health vs Kongo compare each of them with another graded program, and the list of alternatives to Gimme Care ranks the programs closest to Gimme Care on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the yourEra review covers one graded close to these two, at 83.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Gimme Care | Kongo |
|---|---|---|
| WeighScore | 84.6/100 | 83.8/100 |
| Grade | B | B |
| Site position | #15 | #19 |
| Semaglutide | $160 one-month plan; $130/month on three-month plan or $119/month on six-month plan; confirm initial charge and renewal dates | $109 one-month plan or $285 every three months advertised; confirm selected charge and supply. |
| Tirzepatide | $199 one-month plan; $163/month on three-month plan or $149/month on six-month plan; confirm initial charge and renewal dates | $209 one-month or $387 three-month plan advertised; confirm selected charge and supply. |
| Coverage | Advertises all 50 states plus DC; state-specific initial audio/video requirements apply | All 50 advertised; confirm treatment-specific state availability. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Portal pause or cancellation
- Pre-dispense order cancellation
- Unavailable-treatment refund exception
What to consider
- Assigned pharmacy not established
- Support-change notice required
- Refund eligibility is conditional
Strengths
- Regular one-month and prepaid totals published
- Medication, care, supplies and shipping advertised included
- Portal cancellation and clinical messaging
What to consider
- Refund and refill cutoffs need confirmation
- Operator and footer entities need clarification
- Assigned clinician and pharmacy not established
- Telephone support marked coming soon
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.